Clear cell sarcoma (CCS) of soft tissue is a rare sarcoma with morphologic similarities to malignant melanoma but a distinct genetic background including a chromosomal translocation, t(12;22)(q13;q12), or a resultant EWSR1-ATF1
Immunohistochemically, the tumors were consistently positive for S-100 protein (33/33) and variably or focally for HMB45 (32/33) , microphthalmia transcription factor (26/32), Melan A (23/32), CD57 (25/33), bcl-2 (30/32), synaptophysin (14/32), CD56 (7/32), epithelial membrane antigen (12/33), cytokeratin (AE1/AE3) (1/32), CD34 (3/32), c-erbB-2 (10/32), c-kit (5/32), and c-met (5/32). a-Smooth muscle actin, desmin, and cytokeratin (CAM5.2) were negative. Reverse transcription-polymerase chain reaction using RNA extracted from formalin-fixed, paraffin-embedded tissues demonstrated transcripts of the EWSR1-ATF1 (31/33) or EWSR1-CREB1 fusion gene (2/33) . In 26 cases with available clinical information, local recurrences and metastases developed in 2 and 15 patients, respectively. Ten patients were dead of the disease, and the overall survival rate was 63% at 5 years. However, no clinicopathologic or molecular variables associated with the patients' prognosis were identified. This study confirms that CCS is an aggressive soft tissue tumor with a melanocytic phenotype and wider morphologic variations than had been generally considered. In cases with unusual histologic findings, molecular detection of the EWSR1-ATF1/ CREB1 fusion genes provides critical information regarding the diagnosis of the tumor. C lear cell sarcoma (CCS), also known as malignant melanoma of soft parts, is a rare but distinct clinicopathologic entity, which has a predilection for occurring in the tendons and aponeuroses of adolescents and young adults. 6, 12 CCS is characterized by a nested or fascicular growth of pale-staining or clear cells displaying phenotypic features shared with malignant melanoma including the presence of melanin, ultrastructural evidence of melanosomes, and the immunohistochemical expressions of S-100 protein and melanoma-associated markers such as HMB-45, Melan-A, and microphthalmia transcription factor (MITF). 11, 17, 25 Therefore, the distinction between CCS and malignant melanoma, especially in a metastatic form with an unknown primary origin, often creates diagnostic challenges.
However, CCS has been shown to be genetically different from malignant melanoma or other tumors of a neuroectodermal or mesenchymal derivation, because a recurrent chromosomal translocation t(12;22)(q13;q12) or a resultant fusion of the EWSR1 gene on 22q12 and the ATF1 gene on 12q13 is specifically detected in most cases with CCS and angiomatoid fibrous histiocytoma (AFH), 11, 17, 18, 21, 25, 28 the latter of which is a distinct soft tissue tumor of intermediate malignancy with a partial myoid phenotype and no melanocytic differentiation. Recently, another variant fusion gene EWSR1-CREB1, probably resulting from a yet unidentified chromosomal translocation t(2;22)(q34;q12), has been found in a subset of CCS that arose exclusively in the gastrointestinal tract and in some AFHs. 1, 2 These characteristic cytogenetic and molecular genetic changes are considered to play a pivotal role in the development of CCS and AFH.
Because of the rarity of CCS and relatively limited number of cases previously examined, further characterization of the tumor on the basis of the accumulated examples is necessary to strengthen the understanding of this particular sarcoma and to facilitate making accurate diagnosis. This study analyzed 33 cases of CCS occurring in the soft tissues by combined clinicopathologic, immunohistochemical, and molecular approaches.
MATERIALS AND METHODS
Thirty-three CCSs occurring in 30 Japanese and 3 Taiwanese patients were retrieved from the consultation files of the authors and institutional archives. We selected the cases in which the diagnosis of CCS was suggested by the referring pathologists. Paraffin blocks or recently prepared histologic sections of primary tumors were available in all but 2 cases. In the remaining cases in which the tumor arose primarily in the hand or knee, only paraffin blocks of metastatic deposits from the back and lower leg were available and used for the following histopathologic and molecular analyses. Five cases of cutaneous malignant melanoma arising in the distal extremities were included as controls for the immunohistochemical and molecular analyses.
In the current immunohistochemical assessment, the following primary antibodies were applied to deparaffi-nized histologic sections with or without preceding standard antigen retrieval (AR) or protease digestion (PD): anti-S-100 protein (polyclonal, 1:200, DAKO Cytomation, Kyoto, Japan, no pretreatment), antimelanoma (HMB45, 1:100, Enzo Life Sciences, Farmingdale, NY, no pretreatment), anti-Melan A (A103, 1:25, Novocastra, Newcastle Upon Tyne, UK, with AR), anti-MITF (D5, 1:100, Neomarker; Fremont, CA, with AR), antisynaptophysin (SY38, 1:100, DAKO Cytomation, no pretreatment), anti-a-smooth muscle actin (1A4, 1:150, DAKO Cytomation, no pretreatment), antidesmin (D33, 1:100, DAKO Cytomation, no pretreatment), anticytokeratin (CAM5.2, prediluted, Becton Dickinson, San Jose, CA, with PD), anticytokeratin (AE1/AE3, 1:50, DAKO Cytomation, with PD), anti-epithelial membrane antigen (E29, 1:100, DAKO Cytomation, no pretreatment), anti-CD34 (QBEND10, 1:100, Immunotech, Marseilles, France, no pretreatment), anti-bcl-2 (124, 1:30, DAKO Cytomation, with AR), anti-CD56 (MOC-1, 1:100, DAKO Cytomation, with AR), anti-CD57 (HNK-1, 1:10, Becton Dickinson, Franklin Lakes, NJ, no pretreatment), anti-c-erbB-2 (polyclonal, 1:100, Zymed, South San Francisco, CA, with AR), anti-c-Kit (polyclonal, 1:100, DAKO Cytomation, with AR), and anti-Met (C-28, 1:100, Santa Cruz Biotechnology, Santa Cruz, CA, with AR). Immunostaining was accomplished by incubation with a labeled polymeric secondary antibody (EnVision, DAKO Cytomation) and 3,3 0 -diaminobenzidine solution, followed by nuclear counterstaining with hematoxylin.
For the molecular detection of EWSR1-ATF1 or EWSR1-CREB1, reverse transcription-polymerase chain reaction was performed using the formalin-fixed, paraffinembedded tumor tissues as previously described with minor modifications. 32 Briefly, total RNA was extracted from the formalin-fixed, paraffin-embedded tissues using the Trizol reagent (Invitrogen Japan, Tokyo, Japan) after preheating at 951C for 10 minutes and subsequent protein digestion with 10 mL of proteinase K (100 mg/mL) at 551C for 30 minutes, and was transcribed into cDNA. Sequences of the primers to amplify transcripts of the EWSR1-ATF1 and EWSR1-CREB1 are shown in Table 1 . 2, 7, 27 The primers were used in the following combinations that could detect variable transcripts of the fusion genes in CCSs; EWSR1-exon 8 forward and ATF1-exon 4 reverse for detection of type 1 fusion transcript of the EWSR1-ATF1, EWSR1-exon 7 forward and ATF1-exon 5 reverse for type 2, EWSR1-exon 9 forward and ATF1-exon 5 reverse for type 3, EWSR1exon 7 forward and ATF1-exon 7 reverse for type 4, and EWSR1-exon 7 forward and CREB1-exon 7 reverse for that of the EWSR1-CREB1. The sequences of the polymerase chain reaction products were confirmed using an automated sequencing system (ALF express, Pharmacia Biotech, Uppsala, Sweden).
The following clinicopathologic parameters were statistically assessed for their potential prognostic value using Fisher exact test; age, sex, anatomic location, tumor size, main histologic growth pattern, minor or unusual histologic variation, tumor necrosis, grade, mitotic activity, and type of the fusion gene transcript. The patient survival rate was calculated using the Kaplan-Meier method.
RESULTS

Clinical Findings
The clinical features of the 33 cases are summarized in Table 2 . There were 20 males and 13 females (a 1.5:1 male predominance) with ages ranging from 13 to 73 years (median, 30 y). More than 70% of the patients were less than 40 years old.
Most tumors were located in the deep soft tissues of the extremities, and 7 tumors (23%) arose in the trunk or limb girdle. The median tumor size was 4 cm (range, 1 to 15 cm). The status at surgery and clinical follow-up information were available in 26 cases with a mean postoperative duration of 38 months (range: 3 to 171 mo). The tumors locally recurred at least once in 2 cases. Lymph node and/or distant metastases were present at surgery in 1 case and developed postoperatively in another 14 cases. Ten patients died of CCS as a result of extensive or disseminated metastatic diseases.
Pathologic Findings
The tumors were mainly located in the aponeurotic and tendinous structures and/or in the skeletal muscle. In 19 cases (57%), the tumors were composed entirely or mainly of compact nests or short fascicles of short spindle cells often separated by fibrosclerotic bands or septa ( Fig. 1 ). In addition, a diffuse or sheetlike growth pattern of much plumper, epithelioid cells was present at least focally in 16 tumors (48%), and was predominant in 14 (42%, Fig. 2 ). The tumor cells were mostly uniform, and had vesicular nuclei containing prominent nucleoli and clear or pale-staining or eosinophilic cytoplasm. In 14 tumors (42%), a variable number of giant cells possessing a wreath of peripherally placed multiple nuclei were present (Fig. 3A) . Occasional tumor cells with bizarre pleomorphic nuclei were identified in 7 tumors (Fig. 3B ). Intracytoplasmic melanin pigments were found focally in 16 tumors (48%). Rhabdoid tumor cells with eosinophilic glassy or globular cytoplasm and eccentric vesicular nuclei were present in 8 cases (24%, Fig. 4 ). Alveolar structures of round to polygonal tumor cells due to the loss of cellular cohesion were identified in 3 cases (Fig. 5 ). In 2 cases, a solid sheetlike growth pattern of palestaining or clear cells with a lymphocyte-rich fibrovascular stroma, simulating seminoma, was focally seen (Fig. 6 ). Fourteen tumors (42%) contained foci or areas of tumor necrosis, which were often associated with the histologic variations described above (7 cases). The median mitotic rate was 2 mitoses/10 high-power fields (HPF) (1 HPF = 0.096 mm 2 , range: 0 to 43/10 HPF, mean: 4/10 HPF), and 2 tumors showed more than 10 mitotic figures/10 HPF. According to the grading system of the French Federation of Cancer Centers, 25 tumors were categorized into grade 2 and 8 were grade 3 ( Table 2 ).
Immunohistochemical Findings
The immunohistochemical results are summarized in Table 3 . All tumors were positive for S-100 protein, generally displaying a diffuse staining pattern. Immunoreactivity for HMB45 was seen at least focally in all but one tumor. Melan A and MITF were expressed in many cases (71% and 81% of cases, respectively) including the HMB45-negative tumor. In addition, most tumors (93%) were positive for bcl-2, which invariably showed a diffuse or intense staining pattern (Fig. 7) . The expression of synaptophysin and CD57 was detectable in modest subsets of the tumors (43% and 75%, respectively), whereas CD56 and CD34 were expressed in occasional or rare examples. Focal staining for epithelial membrane antigen and cytokeratin (AE1/AE3) was seen in 12 (36%) of the 33 cases and one (3%) of the 32 cases, respectively. The tumors were consistently negative for a-smooth muscle actin, desmin, and keratin 8 (CAM5.2). Proteins of tyrosine kinase receptors such as c-erbB-2, c-kit, and c-met were focally expressed in minor fractions of the tumors (15% to 30%).
Molecular Findings
Characteristic fusion gene transcripts were detectable in all of the tumors analyzed ( Table 2 , Figs. 8, 9 ); EWSR1-ATF1 transcripts were identified in 31 cases 
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Clear Cell Sarcoma of Soft Tissue (only type 1 fusion in 15 CCSs, type 2 in 3, type 3 in 3, types 1 and 2 in 9, and types 1 and 3 in 1) and EWSR1-CREB1 in 2 cases. Type 4 fusion of the EWSR1-ATF1 was not detected in any case. Despite detectable transcripts of the housekeeping genes (phosphoglycerate kinase, porphobilinogen deaminase), no fusion transcript was found in the 5 cutaneous malignant melanomas examined.
Statistical Analysis
Either distant or lymph node metastasis was used as the end point for the statistical analysis. No significant prognostic value was identified according to sex, age (< vs. Z median age), anatomic location (extremities vs. trunk or limb girdle), tumor size (< vs. Z median size), predominant growth pattern (fascicular vs. sheetlike), histologic variation (with rhabdoid or pleomorphic cells vs. no rhabdoid or pleomorphic cells), tumor necrosis, mitotic activity (< vs. Z median mitotic rate), histologic grade (grade 2 vs. 3), and variants of the fusion gene transcript (type 1 with or without other types vs. type 2 or type 3 or EWSR1-CREB1). The overall survival rate was 63% at 5 years or 25% at 10 years.
DISCUSSION
The data of the current analysis not only confirms the previously described clinicopathologic and molecular genetic features of CCS, 6, 11, 12, 17, 25 but also provides some interesting or novel findings that further the understanding of this unique sarcoma.
The epidemiologic and prognostic features of the current CCSs are almost consistent with those assessed previously; the tumors were relatively small and occurred most frequently in the deep soft tissues of the extremities of young adults. 6, 12 Although approximately equal sex distribution or a slight female predominance is a general feature of this sarcoma, male patients were predominant in this series and in some other studies. 13, 20 CCS is an aggressive neoplasm with a mortality rate ranging from 39% to 74% in the previous largest series and it was 43% in this study. 6, 12, 20, 23, 26, 29 Histologically, the current tumors were characterized by a nested to fascicular growth pattern of fusiform tumor cells and/or a diffuse sheetlike fashion of much plumper polygonal or epithelioid cells, which are typical or well-documented microscopic features of CCS. The tumor cells are usually uniform and have minimal or only slight nuclear pleomorphism. However, significantly pleomorphic tumor cells other than multinucleated giant cells with peripherally placed nuclei may be present in CCS. 23, 29 It has been also suggested that tumor cells in a recurrent or metastatic lesion tend to become pleomorphic. 12 In the current series, however, 7 primary tumors contained variable number of bizarre pleomorphic tumor cells.
Other previously described morphologic variations of CCS include an alveolar pattern due to loss of cellular cohesion, a microcystic pattern, and the presence of mucoid material pooled in the intercellular spaces, the former of which was present in 3 examples in the current study. 8, 12, 23, 29 Notably, in 2 cases of CCS, the tumors were composed of solid sheets of clear cells with a lymphocyte-rich fibrovascular stroma, similar to seminoma or dysgerminoma. In addition, one-fourth of the CCSs contained a variable number of rhabdoid cells, which has been poorly described in CCS, although tumor cells with a similar histologic appearance were illustrated in some other studies. 12, 23, 29 It therefore seems that CCS may display the above unusual histologic appearances, and careful scrutiny is necessary to identify the more typical or conventional features of CCS in a given tumor.
It is intriguing to consider whether the clinicopathologic variables may be associated with the outcome of the patients. Large tumor size and the presence of tumor necrosis have been repeatedly suggested to be adverse prognostic factors. 12, 23, 30 Recent large studies have added the depth of the tumor, sex, TNM stage, surgical margin, mitotic index, and histologic grade to the factors. 7, 20 However, the present study failed to identify prognostic significance in such clinicopathologic parameters. This may be due to the relatively small sample size of the cases that were collected from a variety of medical institutions in which possible diverse treatments and follow-up studies were undertaken.
In the immunohistochemical study, melanocytic differentiation of CCS was further supported by invariable positivity for S-100 protein followed by frequent expression of melanoma-associated markers such as HMB45, MITF, and Melan A. Consistently negative immunohistochemical expressions of a-smooth muscle actin and desmin render the current tumors different from perivascular epithelioid cell tumor (PEComa or also referred to as so-called clear cell myomelanocytic tumor) that may share similar histologic and immunohistochemical features with CCS. 14 Although PEComa usually lacks expression of S-100 protein, Folpe et al 14 have recently reported that one-third of their PEComas were positive for S-100 protein and smooth muscle actin. One (case no. 31) with a huge pelvic tumor posed a diagnostic challenge because such an anatomic location is unusual for CCS but common for PEComa. However, the immunohistochemical features of this case (eg, S-100 protein-positive and a-smooth muscle actin/desmin-negative) were more consistent with CCS than PEComa. The diagnosis was further reinforced by molecular detection of the EWSR1-CREB1 fusion transcript.
An additional immunohistochemical feature of CCS in the present study was almost invariable and diffuse expression of bcl-2, which has not been clearly described in this type of sarcoma. Although bcl-2 is an inner mitochondrial membrane protein with a functional role in blocking apoptosis, 31 the actual role of this protein in CCS is unknown. The bcl-2 gene has been recently shown to be a direct transcriptional target of MITF, 24 and expressed bcl-2 may exert its function as a survival factor of cells of the melanocytic lineage.
It has been recently shown that c-kit immunoreactivity is negative in CCS but frequently positive in melanoma, suggesting the utility of c-kit immunostaining as a diagnostic tool to differentiate these tumors. 16 However, c-kit was expressed in 5 cases of our series, and our data and others could not support such a diagnostic value of this receptor protein. 19, 30 The chromosomal translocation t(12;22)(q13;q12) or the resultant fusion gene EWSR1-ATF1 is the hallmark of CCS, 3, 33 and variable transcripts of the EWSR1-ATF1 were successfully identified in more than 90% of the current series using formalin-fixed, paraffinembedded tumor tissues. The EWSR1-ATF1 fusion protein consists of the N-terminal region of EWSR1 containing a strong transcriptional activation domain fused to the basic leucine zipper (bZIP) DNA-binding and dimerization domain of the ATF1 transcription factor. Although the expression of ATF1 is regulated by cAMP under normal conditions, the EWSR1-ATF1 protein is constitutively expressed under the control of the strongly and broadly active EWSR1 promoter, leading to dysregulated expression of genes normally controlled by cAMP or ATF1. 5, 15, 22 It has recently been shown that the EWSR1-ATF1 protein constitutively induces the expression of MITF in CCS and plays a crucial role in melanocytic differentiation and growth or survival of tumor cells. 9 According to differences in the location of the break point, 4 types of the EWSR1-ATF1 fusion transcript have been identified. Although types 1 to 3 have been recurrently detected, 3, 7, 27 only a single case with type 4 transcript has been described in the literature. 27 Besides, the tumor may harbor multiple transcript types due to alternative splicing. In the present series, the type 1 fusion transcript was more frequently detectable than other types, and approximately one-third contained multiple fusion transcripts, which is consistent with the previous studies. 7, 27 As suggested by Coindre et al, 7 no significant association between the transcript type and patient's outcome was found.
It is notable that transcripts of a variant fusion gene, EWSR1-CREB1, were identified in 2 of the CCSs that arose in soft tissues. Antonescu et al 2 has recently described this variant in 3 tumors, all of which were located in the lower digestive tract. Like ATF1, CREB1 is a member of the bZIP subfamily of transcription factors and binds cAMP response elements of multiple genes involved in cellular proliferation, differentiation, transformation, and stress response. 10 Therefore, EWSR1-ATF1 and EWSR1-CREB1 fusion proteins may exert a similar functional property, although the kinase-inducible domain of the bZIP family is retained in EWSR1-ATF1 but not in EWSR1-CREB1. 3 The predicted structure of the detected EWSR1-CREB1 in this study was identical to that described by Antonescu et al. 3 Their cases, however, showed little or no melanocytic differentiation, whereas it was evident histologically and/or immunohistochemically in both of the cases with the EWSR1-CREB1 described herein. Such a phenotypic difference between tumors might have reflected their potentially divergent precursor cells as has been also suggested between CCS and AFH. 4, 18 In summary, a clinicopathologic and molecular analysis of CCS was conducted using accumulated 33 FIGURE 9 . Partial sequences of the reverse transcriptionpolymerase chain reaction products. Representative results of a distinct fusion type [A, EWSR1-ATF1 type 1 (case no. 3); B, type 2 (case no. 11); C, type 3 (case no. 9); and D, EWSR1-CREB1 (case no. 1)] are shown.
formalin-fixed, paraffin-embedded tumor tissues and wider panels of antibodies and primer sets for reverse transcription-polymerase chain reaction. The data confirmed that CCS is an aggressive soft tissue tumor showing a melanocytic phenotype and more variable histologic and immunohistochemical features than described previously, and that the tumor is genetically characterized by the EWSR1-ATF1 or the EWSR1-CREB1, both of which are considered to be valuable diagnostic molecular adjuncts for identifying CCS of soft tissue.
